Cobalis Initiates PreHistin Phase III Trials
Posted on: Wednesday, 26 July 2006, 12:00 CDT
Cobalis has enrolled its first patient into its twin phase III clinical trials of its lead anti-allergy medication PreHistin.
The randomized, double blind, placebo-controlled studies are intended to assess the efficacy and safety of pre-seasonal treatment with PreHistin on moderate to moderately severe seasonal ragweed allergy patients.
The 10-week clinical trials are being conducted at 23 sites across the central, southern, and eastern US and will utilize electronic diary records to assess improvement in total nasal symptom score (TNSS).
Approximately 1,600 to 2,000 patients in total will be randomized into the twin studies to receive either placebo or 3.3mg sublingual PreHistin twice daily for three weeks prior to the onset of the ragweed allergy season, and for an additional three weeks into the allergy season.
As in the company's previous phase III trial, the studies' primary end point will be improvement in TNSS in weeks four, five and six. To determine the lasting effect, a secondary endpoint will measure the symptomology for patients over the last four weeks of the study. These twin studies are anticipated to fulfill the requirement for the two phase III double blind, placebo controlled studies typically required for FDA approval.
"The results of our previous phase III clinical trial of PreHistin in patients with Mountain Cedar seasonal allergies were encouraging, and we are eager to prove the potential of PreHistin as a treatment for nasal allergy symptoms in these seasonal ragweed studies," said Cobalis CEO, Dr Gerald Yakatan.
Source: Datamonitor
Related Articles
- GTx Presents Bone Turnover Marker Data and Additional PSA Progression Safety Analysis for Toremifene 80 Mg Phase III ADT Clinical Trial
- Introgen Presents Top Line Data From Phase III ADVEXIN(R) Clinical Trial
- Gentium Provides Clinical Update on Phase III Defibrotide Clinical Program
- AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
- Phase III Bronchitol Clinical Trial Fully Recruited
- Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
- AVAX Technologies Launches Global Phase III Registration Clinical Trial of M-Vax in Metastatic Melanoma
- InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
- Cobalis Corp. PreHistin(TM) Significantly Reduces Allergy Symptoms in 714 Patient Phase 3 Clinical Trial
- Newron Pharmaceuticals Completes Enrollment in Safinamide Phase III Pivotal Clinical Trial for Parkinson's Disease
 |
 |
User Comments (0)
RSS Feeds